Viral Hepatitis

You have full text access to this OnlineOpen article

Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up†

  1. Kathleen E. Corey1,3,
  2. Erin Kane3,
  3. Craig Munroe4,
  4. Lydia L. Barlow1,
  5. Hui Zheng2,3,
  6. Raymond T. Chung1,3,‡,*

Article first published online: 10 AUG 2009

DOI: 10.1002/hep.23219

Issue

Hepatology

Hepatology

Volume 50, Issue 4, pages 1030–1037, October 2009

Additional Information

How to Cite

Corey, K. E., Kane, E., Munroe, C., Barlow, L. L., Zheng, H. and Chung, R. T. (2009), Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up. Hepatology, 50: 1030–1037. doi: 10.1002/hep.23219

Author Information

  1. 1

    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA

  2. 2

    MGH Biostatistics Center, Massachusetts General Hospital, Boston, MA

  3. 3

    Harvard Medical School, Boston, MA

  4. 4

    Department of Medicine, Massachusetts General Hospital, Boston, MA

  1. ‡

    fax: 617-643-0446.

*Massachusetts General Hospital, Warren 1007, 55 Fruit Street, Boston, MA 02114

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 28 SEP 2009
  2. Article first published online: 10 AUG 2009
  3. Accepted manuscript online: 10 AUG 2009 12:00AM EST
  4. Manuscript Accepted: 27 APR 2009
  5. Manuscript Received: 10 FEB 2009

Funded by

  • Bristol-Myer-Squibb Virology Fellowship
  • Roche Laboratories
  • Schering-Plough

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (115K)

References

  • 1
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705–714.
  • 2
    Diaz O, Delers F, Maynard M, Demignot S, Zoulim F, Chambaz J, et al. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol 2006; 87: 2983–2991.
  • 3
    Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 6919–6928.
  • 4
    Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96: 12766–12771.
  • 5
    Molina S, Castet V, Fournier-Wirth C, Pichard-Garcia L, Avner R, Harats D, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007; 46: 411–419.
  • 6
    Dubuisson J, Penin F, Moradpour D. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol 2002; 12: 517–523.
  • 7
    Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 2003; 100: 15865–15870.
  • 8
    Wang C, Gale M Jr, Keller BC, Huang H, Brown MS, Goldstein JL, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 2005; 18: 425–434.
  • 9
    Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. HEPATOLOGY 2008; 47: 1437–1445.
  • 10
    Maggi G, Bottelli R, Gola D, Perricone G, Posca M, Zavaglia C, et al. Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 1996; 28: 436–440.
  • 11
    Marzouk D, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007; 56: 1105–1110.
  • 12
    Munroe C, Chan J, Zheng, H, Chung RT. Incidence of hyperlipidemia in chronic hepatitis C and response to anti-viral therapy in combination with HMG-CoA reductase inhibitors [Abstract M1779]. Presented at: Digestive Disease Week 2007; May 19-24; Washington, DC.
  • 13
    National Heart, Lung and Blood Institute. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Bethesda, MD: National Institutes of Health; 2004.
  • 14
    Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823–2828.
  • 15
    Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 1997; 261: 159–165.
  • 16
    Floris-Moore M, Howard AA, Lo Y, Schoenbaum EE, Arnsten JH, Klein RS. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS 2007; 21: 479–491.
  • 17
    Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. HEPATOLOGY 2006; 44: 335–340.
  • 18
    Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997; 157: 792–796.
  • 19
    Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307.
  • 20
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–1622.
  • 21
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
  • 22
    Seyam MS, Freshwater DA, O'Donnell K, Mutimer DJ. Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*. J Viral Hepat 2005; 12: 531–535.
  • 23
    Soardo G, Pirisi M, Fonda M, Fabris C, Falleti E, Toniutto P, et al. Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C. J Interferon Cytokine Res 1995; 15: 705–712.
  • 24
    Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34–47.
View Full Article (HTML) Get PDF (115K)